Overcoming CMC hurdles in TIL therapy: strategic insights from a clinical-stage biotech

With the ever-growing need for precise, personalized, and effective therapeutics, tumor-infiltrating lymphocyte (TIL) therapy offers a promising approach to treating solid tumors by harnessing the patient’s own immune cells and addressing challenges such as tumor heterogeneity. This article explores GRIT’s pipeline of personalized therapies, and a comprehensive strategy to overcome key CMC challenges in TIL development—including tumor sampling, feeder cell safety, potency assays, and cryopreservation. Clinical outcomes, scalable manufacturing solutions, and future directions for automation and process optimization in TIL-based immunotherapy are also explored.

Please enter your email to access content Read now